Ann: IMUGENE LICENSES CAR T DIRECTED OV THERAPY FOR SOLID TUMOURS, page-200

It is worth listening to the 19 May 2021IMU Investor Webinar several times as it provides more and sometimes easier to understand information than just reading the presentation slides. The Q&A session that starts around mid-way through the webinar provider answers to many important questions at the forefront of the minds of investors.

I don’t think a copy of the webinar is on the IMU site yet, so you will need to register your details at the following link to view and listen to it.

https://us02web.zoom.us/webinar/register/WN_3MnBYj03SXuJtezpEbcERg

I note that in some of the posts in the various IMU threads that some people seem confused about whether IMU is becoming a CAR T company.LC answered this question clearly: NO.

Irefer to the following slide in the webinar slide presentation pack:

Suggest listening to the segment in the webinar video by Saul “Cancer Asskicker”Priceman between 4:50 to 6:50 minutes.

The key / important points I took away from Saul's comments are:

- therapeutic window of opportunity: 24h | 48h | 72H

-CF33 infects 100% of the cells

-CF33 kills 50 to 60% of the cancer cells alone

-100% of cancer cells express CF33 CD19, exposing the remaining cancer cells to CD19 CAR T drugs

-Allows a CAR T to come in and “mop up & eradicate” the rest of the cancer cells

So, this is what I think this means:

-CF33 is the primary cancer treatment drug (50 to 60%)

- CF33 CD19 is the “dam buster” marker drug that enables a CAR T drug to see, seek and destroys the rest of the cancer cells

- The CAR T drug is the secondary drug – can’t do it without CF33 CD19

-Drug sequence of impact importance:1. CF33, 2. CF33 CD19 & 3. CAR T drug

GLTAHs